Axoft, a Cambridge, Massachusetts company founded in 2021 to build implantable brain-computer interfaces, announced on 29 April that it has raised an oversubscribed $55 million Series A led by C.P. Group Innovation, which Bloomberg described as primarily based in Thailand. Alumni Ventures, the Stanford President’s Venture Fund, Hillhouse Investment and Gaorong Ventures also took part, and Axoft says its total funding now exceeds $60 million. In the same week, Bloomberg reported that Axoft has tested its brain implant on four patients at a hospital in Shanghai, and that this was the first time a US brain implant company had disclosed testing a device in China.
Two stories sit inside this news, and they should be kept apart. The first is about capital: a Thailand-based lead investor and a China-based fund on the Series A of a US company that plans to file with the FDA in 2027. The second is clinical, and narrower than the word implant suggests. Axoft’s tests so far have been temporary. Bloomberg reported that Axoft has tested the device temporarily on 11 patients, including the four in Shanghai. In its FINESSE study at The Panama Clinic, Axoft placed its probes in four patients already having brain tumour surgery and recorded 20 minutes of brain activity.
What Axoft is building
Fleuron is Axoft’s proprietary polymer, based on work co-founder Jia Liu began at Stanford University, which has licensed the technology exclusively to Axoft. Axoft says it is up to 10,000 times softer than the polyimide used in existing brain implants, and that it gives eight times more region access and 32 times more sensors or stimulators per thread than standard flexible probes, with more than 60 per cent less signal attenuation than polyimide. Axoft says the material meets ISO 10993, the international standards for evaluating the biocompatibility of medical devices, and it sells the material to other researchers. The company’s case is that rigid implants cause scarring and shift in the brain over time, which reduces the quality and volume of data they collect, and that a softer material holds up better.
Dr Paul Le Floch, Axoft’s co-founder and chief executive, said: “This new funding and strategic support from C.P. Group Innovation allows us to expand our work into global markets.” Axoft says it will use the money to expand its clinical trials internationally, work toward US regulatory approval and build a good manufacturing practice facility in Boston to make its implants in volume. It also lists clinical research collaborations with Mass General Brigham, including cortical mapping and mapping where seizures start around tumours.
The Shanghai tests
Le Floch told Bloomberg that Axoft chose to work in China partly because of how quickly it could run tests there. The work was done through a local partner company, and he declined to name the partner or the hospital. He said Axoft plans to study the device in more patients in China this year and is planning several clinical trials in the country. Axoft has also tested its device in the US and Panama.
The capital
C.P. Group Innovation led the round. Gaorong Ventures, a China-based fund, invested because of Liu’s work in flexible electronics, its senior vice president Hongbo Zhao told Bloomberg. Liu supervised Le Floch’s PhD at Harvard, and the two co-founded Axoft with Tianyang Ye. The investment manager Hillhouse Investment also took part, alongside two US investors, Alumni Ventures and the Stanford President’s Venture Fund. Axoft declined to share its valuation with Bloomberg.
Bloomberg described the Shanghai tests as a rare sign of cooperation while the US and China compete to lead in neurotechnology, which the Chinese government has called a strategic priority.
Forward Radar: What to watch
Whether the Shanghai work moves from temporary tests to longer implants, and under which approvals, Chinese, US or both.
Whether other US implant companies disclose clinical work in China.
Whether C.P. Group Innovation brings Axoft into Thailand or the wider Southeast Asian market, through clinical sites or hospital partners.
Axoft’s FDA submission, which Le Floch told Bloomberg is planned for 2027.
Correction, 20 November 2026: An earlier version of this article said Axoft had tested its probe on one patient in Shanghai, the figure in Bloomberg’s report as first published on 29 April. Bloomberg corrected its report on 1 May to four patients in Shanghai, out of 11 tested so far. The earlier version also said the Shanghai test was disclosed in Axoft’s funding announcement, which did not mention China, and described it as a 20-minute recording; the 20-minute recordings were from Axoft’s study in Panama. Its headline, which said Axoft ran its first acute implant in Shanghai, has been changed. The earlier version also called the Shanghai test the first publicly confirmed clinical use of US-developed implant material in China, likened Axoft’s approach to Synchron’s and Precision Neuroscience’s, described C.P. Group and Hillhouse with superlatives and characterisations that could not be verified, and quoted Paul Le Floch with words cut from the middle of his statement without marking the cut. These and other passages have been corrected or removed.
Sources
Primary:
- Axoft via Business Wire: Axoft secures $55M Series A, 29 April 2026
- Axoft via Business Wire: first four cases of the FINESSE first-in-human study, 22 April 2025
- Axoft via Business Wire: commercialisation of Fleuron under an exclusive licence agreement with Stanford University, 14 May 2025
Coverage:
- Bloomberg via The Boston Globe: Massachusetts brain implant company tests in China in apparent first, 29 April 2026 (first version)
- Bloomberg Law: US brain implant company tests with patients in China (Correct), 1 May 2026
- Bloomberg via The Star: US brain implant company tests with patients in China, 4 May 2026
Later InsideBCI coverage: